Certara (CERT) Q2 2026 Earnings Call Transcript

Certara reported Q2 2026 revenue of $93.3M (+1% YoY) with software revenue up 4% to $48.8M while services revenue fell 3% to $44.5M. Adjusted EBITDA was $26.2M with margin down to 28.1%, and FY2026 guidance was reaffirmed for revenue at $367M–$382M (0%–4% growth) while adjusted EBITDA margin was lowered to 29%–31% (from 30%–32%) due to the divestiture. The company also cut its workforce by ~5% for ~$13M run-rate savings and continued capital returns via $17.4M Q2 buybacks, completing a prior $100M program and adding a new $50M authorization.

Analysis

The setup is less about this quarter’s numbers and more about whether Certara can convert a software-heavy mix into a higher-quality recurring revenue story. The obvious near-term winner is the stock if the market decides the divestiture removed a drag and leaves a cleaner earnings base; the less obvious loser is the legacy services engine, which may keep suppressing narrative quality until the new commercial model proves it can turn pipeline into durable bookings. Second-order, the AI productivity claims matter only if they are monetized into faster product cadence and higher attach rates; otherwise they mainly support margins, not multiple expansion.

The key catalyst path is 1-3 months: backlog/pipeline conversion, cloud implementations, and whether software bookings continue to outrun services through Q3. If that happens, CERT can be re-rated as a niche vertical software asset rather than a mixed services company. Over 6-18 months, the real debate is whether the company can sustain high-teens to low-20s growth in software bookings; if not, buybacks and margin help will cap downside but won’t justify a premium multiple.

Contrarian view: the market may be underestimating how long it takes for regulatory-science adoption to translate into revenue, but it may also be over-discounting the strategic value of deeper FDA/EMA standardization. The biggest falsifier is not the AI story; it is a failure of software ARR/bookings to accelerate while services remain soft. If the next two quarters don’t show cleaner conversion, the stock can drift despite capital returns.

Best risk/reward is to treat this as a conditional long rather than a momentum buy. The buyback provides a floor, but execution needs to prove itself before the multiple can widen.

Key Decisions for Investors

• Watch-to-buy CERT on post-earnings weakness: initiate only if software bookings/ARR remain positive next quarter; risk/reward improves if the stock sells off on the headline guide but the software mix stays intact.
• Long CERT vs. short a broader life-science services proxy (e.g., IQV or MEDP if liquidity/borrow work) for a 1-3 month pair: thesis is software mix and buybacks outperform labor-intensive services exposure if biotech funding remains choppy.
• If holding CERT, size it as a margin-improvement story with a 6-18 month horizon; trim if Q3/Q4 do not show services pipeline conversion or if software growth reverts to low single digits.
• Avoid paying up for NVDA on this specific event: the partnership is strategically interesting but too early to underwrite meaningful near-term revenue; treat as an ecosystem option, not a catalyst.
• Falsifier alert: if the next two quarters show software bookings decelerating or consolidated revenue guidance cuts again, exit the long thesis and assume the market will value CERT like a low-growth hybrid rather than a software compounder.